Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma
Stopped The study sponsor withdrew funding early, forcing this study to stop all activity and close pre-maturely.
Conditions
Interventions
- DRUG: Venetoclax Oral Tablet [Venclexta]
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators